文献速递中医内科中药与中成药合理使用

丹参川芎嗪注射液辅助治疗早期糖尿病肾病的系统评价与Meta分析

Efficacy and safety of Salvia miltiorrhiza (Salvia miltiorrhiza Bunge) and ligustrazine injection in the adjuvant treatment of early-stage diabetic kidney disease: A systematic review and meta-analysis.
PubMed 文献 · J Ethnopharmacol · 2021-06-18

本研究通过系统评价与Meta分析评估丹参川芎嗪注射液辅助治疗早期糖尿病肾病的疗效与安全性。共纳入22项试验1939例患者,结果显示联合常规西药在降低尿白蛋白排泄率、血肌酐、β2微球蛋白及炎症因子方面优于单用常规西药,但受纳入研究质量限制,结论需高质量大样本随机对照试验进一步验证。

要点

  • 丹参川芎嗪注射液联合常规西药可改善早期糖尿病肾病患者尿白蛋白排泄率等指标。
  • 联合治疗还可降低血肌酐、β2微球蛋白及白介素-6等炎症因子水平。
  • 现有证据提示辅助治疗安全有效,但研究质量有限,需高质量大样本随机对照试验验证。

核心结论

  • 基于现有证据,丹参川芎嗪注射液辅助治疗早期糖尿病肾病安全有效。
  • 因纳入研究质量限制,上述结论需更多高质量大样本随机对照试验进一步验证。

研究设计与样本

  • 系统评价与Meta分析,遵循PRISMA清单。
  • 检索PubMed、Cochrane图书馆及CNKI、SinoMed、万方、VIP等中英文数据库。
  • 共纳入22项试验,1939例患者。
  • 使用RevMan 5.3软件进行Meta分析,Cochrane偏倚风险工具评估质量,Stata 15.0进行敏感性分析和Egger检验。

主要发现

  • 与单用常规西药相比,联合丹参川芎嗪注射液在降低尿白蛋白排泄率方面更优(12项RCT,1181例;SMD=-1.82,95%CI[-2.62,-1.01],P<0.00001)。
  • 联合治疗降低血肌酐(13项RCT,1228例;MD=-13.21 μmol/L,95%CI[-19.58,-6.83],P<0.0001)。
  • 联合治疗降低β2微球蛋白(9项RCT,669例;SMD=-1.45,95%CI[-2.43,-0.48],P=0.003)。
  • 联合治疗降低白介素-6(4项RCT,331例;MD=-6.38 ng/L,95%CI[-9.03,-3.78],P<0.00001)、白介素-18(2项RCT,177例;MD=-29.78 ng/L,95%CI[-41.51,-18.05],P<0.00001)和肿瘤坏死因子-α(4项RCT,331例;MD=-18.03 ng/L,95%CI[-22.96,-13.09],P<0.00001)。

关键数值与推荐

  • 纳入22项试验,共1939例早期糖尿病肾病患者。
  • 联合治疗在降低尿白蛋白排泄率、血肌酐、β2微球蛋白及炎症因子方面均显示统计学差异。

临床怎么用

  • 对于早期糖尿病肾病患者,可考虑在常规西药治疗基础上联合丹参川芎嗪注射液以改善尿白蛋白排泄率及炎症状态。
  • 临床决策时应结合患者具体情况,并注意现有证据质量有限,需谨慎解读。

局限性

  • 纳入研究质量有限,可能影响结论可靠性。
  • 需要更多高质量大样本随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Salvia miltiorrhiza and ligustrazine injection is a compound injection composed of the extract from Salvia miltiorrhiza and Ligusticum striatum (Ligusticum striatum DC.), has been frequently used for the adjuvant treatment of early-stage diabetic kidney disease (DKD) in China. Safety and efficacy studies in terms of evidence-based medical practice have become more prevalent in application to Chinese Herbal Medicine. It is necessary to assess the efficacy and safety of Salvia miltiorrhiza and ligustrazine injection in the adjuvant treatment of early-stage diabetic kidney disease by conducting a systematic review and meta-analysis of available clinical data. AIM OF THE STUDY: The aim of this systematic review and meta-analysis was to evaluate the efficacy and safety of Salvia miltiorrhiza and ligustrazine injection as an adjunctive therapy to conventional therapies for early-stage DKD. MATERIALS AND METHODS: The Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) checklist was used to structure this study. We searched the English databases PubMed, Cochrane library, and Chinese databases including Chinese journal full text database (CNKI), China Biomedical Documentation Service System (SinoMed), Wanfang digital periodical full text database and Chinese Scientific Journal Database (VIP). Relevant studies were selected based on the inclusion and exclusion criteria. Meta-analysis was performed with RevMan 5.3 software after data extraction and the quality of studies assessment. The quality of the evidence was assessed with the Cochrane risk of bias tool. Sensitivity analysis and Egger's test were performed using Stata 15.0 software. RESULTS: A total of 22 trials were included with 1939 patients. Meta-analysis showed that compared with the control group of conventional western medicine alone, Salvia miltiorrhiza and ligustrazine injection combined with conventional western medicine can achieve better efficacy in the treatment of early-stage DKD, reduce urinary albumin excretion rate (12RCTs, 1181 participants; SMD = -1.82, 95% CI [-2.62, -1.01], P < 0.00001), serum creatinine (13RCTs, 1228 participants; MD = -13.21 μmol/L, 95% CI [-19.58, -6.83], P < 0.0001), β2-microglobulin (9RCTs, 669 participants; SMD = -1.45, 95% CI [-2.43, -0.48], P = 0.003) and reduce interleukin-6 (4RCTs, 331 participants; MD = -6.38 ng/L, 95% CI [-9.03, -3.78], P < 0.00001), interleukin-18 (2RCTs, 177 participants; MD = -29.78 ng/L, 95% CI [-41.51, -18.05], P < 0.00001), tumor necrosis factor-α (4RCTs, 331 participants; MD = -18.03 ng/L, 95% CI [-22.96, -13.09], P < 0.00001), with statistical differences and alleviate the body inflammatory response effectively. CONCLUSION: Based on the existing evidence, that Salvia miltiorrhiza and ligustrazine injection in the adjuvant treatment of early-stage diabetic kidney disease is safe and effective. However, due to the limitation of the quality of the included studies, the above conclusions need to be further verified by more relevant randomized controlled trials with high-quality large samples.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Xie F, Zhang B, Dai S, et al. Efficacy and safety of Salvia miltiorrhiza (Salvia miltiorrhiza Bunge) and ligustrazine injection in the adjuvant treatment of early-stage diabetic kidney disease: A systematic review and meta-analysis. J Ethnopharmacol. 2021. PMID: 34153447. doi:10.1016/j.jep.2021.114346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。